MYCOTOPIA THERAPIES, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.03 USD | -25.00% |
|
-25.00% | +87.50% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Capitalization 1 | 31.32 | 2.666 | 0.2383 |
| Enterprise Value (EV) 1 | 30.8 | 2.935 | 1.05 |
| P/E ratio | -10.7 x | -0.94 x | -0.2 x |
| Yield | - | - | - |
| Capitalization / Revenue | - | - | - |
| EV / Revenue | - | - | - |
| EV / EBITDA | -11.5 x | -1.57 x | -1.89 x |
| EV / FCF | 37,585,258 x | 8,106,417 x | 457,958 x |
| FCF Yield | 0% | 0% | 0% |
| Price to Book | 92.1 x | -3 x | -0.12 x |
| Nbr of stocks (in thousands) | 13,967 | 14,808 | 14,897 |
| Reference price 2 | 2.242 | 0.1800 | 0.0160 |
| Announcement Date | 22-04-14 | 23-03-30 | 24-04-23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Net sales | - | - | - | - | - |
| EBITDA 1 | -0.2514 | -0.1589 | -2.669 | -1.875 | -0.5555 |
| EBIT 1 | -0.2517 | -0.1594 | -2.669 | -1.876 | -0.6167 |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -0.2755 | -0.1572 | -2.821 | -2.751 | -1.181 |
| Net income 1 | 0.004803 | -0.2422 | -2.821 | -2.751 | -1.181 |
| Net margin | - | - | - | - | - |
| EPS 2 | 0.000386 | -0.0191 | -0.2103 | -0.1905 | -0.0794 |
| Free Cash Flow | - | -0.0441 | 0.8195 | 0.362 | 2.292 |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 21-04-15 | 21-04-15 | 22-04-14 | 23-03-30 | 24-04-23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | 0.27 | 0.81 |
| Net Cash position 1 | 0.21 | 0.02 | 0.52 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | -0.1436 x | -1.461 x |
| Free Cash Flow | - | -0.04 | 0.82 | 0.36 | 2.29 |
| ROE (net income / shareholders' equity) | - | -28.4% | -1,742% | 998% | 80.9% |
| ROA (Net income/ Total Assets) | - | -11.9% | -242% | -141% | -29.6% |
| Assets 1 | - | 2.03 | 1.167 | 1.945 | 3.995 |
| Book Value Per Share 2 | 0.0500 | 0.0400 | 0.0200 | -0.0600 | -0.1400 |
| Cash Flow per Share 2 | 0.0200 | 0 | 0.0900 | 0.0300 | 0.0200 |
| Capex | - | - | 0 | - | - |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 21-04-15 | 21-04-15 | 22-04-14 | 23-03-30 | 24-04-23 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- TPIA Stock
- Financials Mycotopia Therapies, Inc.
